Thalia Therapeutics Secures €3.1 Million Funding and Expands Portfolio with Acquisition of Sanmirna Therapeutics

Thalia Therapeutics, a prominent British BioTech company specializing in RNA-based therapeutics and delivery technologies for oncology and cardiovascular diseases, has recently made headlines with the acquisition of Sanmirna Therapeutics and a successful €3.1 million (£2.75 million) fundraising round.

The acquisition of Sanmirna Therapeutics, a move supported by both new and existing investors including Premier Miton, brings miRisten, a cutting-edge microRNA therapeutic candidate for Acute Myeloid Leukaemia (AML), into Thalia’s innovative portfolio. This strategic acquisition is expected to significantly expedite Thalia’s transition into a clinical-stage RNA therapeutics business.

Dr. David Solomon, the esteemed CEO of Thalia, expressed his enthusiasm regarding this transformative opportunity, stating, “This is an exciting and transformative opportunity to accelerate our clinical-stage oncology pipeline and diversify our RNA therapeutics pipeline, providing us with an asset that advances our development timeline by several years compared with our pre-clinical progress to date.”

Thalia Therapeutics’ recent fundraising success and acquisition align with the ongoing trend of robust 2026 European BioTech financings focusing on RNA-related therapeutics, oncology, genetic medicines, and cardiovascular diseases. Notable announcements in this space include STORM Therapeutics’ €47.5 million Series C for RNA-modifying cancer therapies, Engitix’s €21 million Series A extension for cancer and fibrosis programs, Laigo Bio’s €17 million Seed round for cancer and autoimmune therapies, and PlaqueTec’s €4.2 million raise for cardiovascular precision medicine.

Several of these significant 2026 funding rounds have been UK-based, underscoring the country’s position as a hub for therapeutics and platform BioTech activities. Thalia’s participation in this domestic cluster of innovation further solidifies its standing in the industry.

Dr. Solomon further elaborated on the value proposition of the Sanmirna acquisition, highlighting its potential to enhance shareholder value by propelling Thalia into a clinical-stage company with a promising therapeutic approach for AML. The miRisten therapy targets microRNA-126, a key player in AML pathogenesis, addressing a critical unmet medical need in this challenging disease.

Founded in 2014, Thalia has been at the forefront of RNA-based therapeutics, with a focus on oncology and cardiovascular diseases. The addition of Sanmirna represents a significant milestone for the company, introducing a novel RNA therapeutic modality to complement its existing pipeline.

Sanmirna Therapeutics, a US-based clinical-stage BioTech company founded by NLC Health Ventures, has been dedicated to developing innovative microRNA-targeted therapies for oncology indications. Thalia’s acquisition of Sanmirna includes an initial consideration of €4.2 million (£3.675 million), with additional milestone payments of up to €15 million (£13 million) in the future.

Looking ahead, Dr. Solomon emphasized the potential of Thalia’s diversified pipeline, which now includes Nuvec, a cardiovascular product, and the newly acquired miRisten therapy. These assets, at varying stages of clinical development, hold significant promise in addressing substantial market opportunities in the healthcare landscape.

miRisten, designed to selectively inhibit microRNA-126, is currently undergoing evaluation in a Phase 1 clinical trial for relapsed or refractory AML patients. The therapy’s potential to address the urgent medical needs of AML patients is underscored by the disease’s global market opportunity, estimated to reach US$9.8 billion by 2035.

The funds raised by Thalia are earmarked for advancing key aspects of the company’s development plan, including supporting the completion of miRisten’s Phase 1 trial, progressing cardiovascular assets towards FDA approval, and allocating resources for ongoing research and operational expenses.

In conclusion, Thalia’s strategic acquisition of Sanmirna and successful fundraising efforts signal a significant step forward in the company’s mission to revolutionize RNA-based therapeutics for oncology and cardiovascular diseases. With a strong focus on innovation and clinical advancement, Thalia is poised to make a lasting impact in the BioTech industry.